Gilead terminates simtuzumab IPF study

Gilead Sciences Inc. (NASDAQ:GILD) said it stopped a Phase II study of simtuzumab ( GS-6624) to treat idiopathic pulmonary fibrosis. Gilead said a DMC recommended that the study be terminated early due to lack of efficacy, but recommended continuing two trials of simtuzumab to treat non-alcoholic liver steatosis (NASH) and primary sclerosing cholangitis (PSC).

Spokesperson Patrick O'Brien said Gilead expects results from both studies in 2H16. ...